Internship

Fall 2025 Co-Op

Chemical Biology

Confirmed live in the last 24 hours

Bristol-Myers Squibb

Bristol-Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Biotechnology
Healthcare

Cambridge, MA, USA

6-month Co-Op based in Cambridge, MA from July 7th, 2025 to December 12th, 2025.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Trained in molecular and cell biology
  • Experience independently generating precise, reliable data and performing data analysis
  • Hands-on experience in cell culture and characterization of cells from human and animal tissues is desired
  • Two years of cell biology and/or molecular biology course work at the college level, a strong academic record (≥ 3.0 GPA), and at least three semesters of laboratory course work and/or research
  • Self-motivated to learn and contribute, demonstrated examples of independent productivity and team-based interpersonal skills
  • Excellent communication, record keeping, presentation, collaboration and organizational skills
  • Enthusiasm for science, laboratory work and drug discovery
  • Prior laboratory experience in an academic setting and/or biotechnology/pharmaceutical industry
Responsibilities
  • Perform cell-based studies using a variety of laboratory techniques, including mammalian cell culture, Western blotting, ELISA, MSD, genetic engineering (lentiviral, CRISPR, RNAi)
  • Collaborate with a cross-functional team of chemical biologists, chemists, biochemists, and proteomics experts to develop new technologies and discover new targets
  • Maintain thorough scientific records and present at group meetings

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Company Stage

IPO

Total Funding

$33.7B

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS's collaboration with AI Proteins could lead to novel miniprotein-based therapeutics.
  • The $3.5bn agreement with Prime Medicine enhances BMS's cell and gene-therapy pipeline.
  • Karen Costello's appointment may strengthen BMS's commercial strategy in Ireland.

What critics are saying

  • BMS faces legal challenges, including a lawsuit against HRSA and HHS.
  • The dismissal of a $6.4 billion lawsuit could impact BMS's financial standing.
  • Regulatory hurdles may delay the approval of new drugs, affecting market entry.

What makes Bristol-Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases for innovative treatments.
  • The company invests heavily in R&D to develop new drugs and therapies.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?